Director Ian Isaacs filed a Form 4 with the SEC on August 31, 2026, disclosing two open-market sales of Greenlight Capital Re, Ltd. ordinary shares on August 27 and August 28, 2026, executed through the Isaacs Living Trust.
A Form 4 filed on August 31, 2026, disclosed that Ron Gutler, a director of Wix.com Ltd. (NASDAQ:WIX), sold a total of 5,718 ordinary shares on August 27, 2026, under a pre-established Rule 10b5-1 trading plan.
Christopher P. Calvert, Executive Vice President and CFO of Matador Resources Co (NYSE:MTDR), filed a Form 4 on August 31, 2026, reporting a purchase of 2,500 shares of common stock on August 27, 2026, through his 401(k) account.
Gabriel Malka, Chief Operating Officer of Radware Ltd, filed a Form 4 on August 31, 2026, reporting the sale of 6,500 ordinary shares on August 27, 2026.
Travis Dalton, President, CEO, and Executive Chair of Claritev Corp, filed a Form 4 on August 31, 2026, disclosing open-market purchases of 6,450 shares of Class A common stock on August 27 and August 28, 2026, held through a spouse's Individual Retirement Account.
Sweetgreen, Inc. filed a Form 8-K on August 28, 2026, disclosing that its Board of Directors and Compensation Committee approved and adopted a new company-wide Severance Plan effective August 27, 2026, covering designated executive officers under two participation tiers.
Forum Energy Technologies, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 28, 2026, disclosing the filing of a legal opinion from Gibson, Dunn & Crutcher LLP in connection with a prospectus supplement filed the same day.
Deckers Outdoor Corporation filed an 8-K on August 28, 2026, disclosing that it entered into a First Amendment to its existing Credit Agreement on August 27, 2026, increasing its unsecured revolving credit facility to $500 million and extending the maturity date to August 27, …
Trilogy Metals Inc. filed an 8-K on August 31, 2026, disclosing that on August 28, 2026, it entered into a definitive Investment Agreement and Cooperation Agreement with the United States Department of War for a strategic equity investment valued at approximately $17.8 million.
BioMarin Pharmaceutical Inc. filed a Form 8-K on August 31, 2026, disclosing that on August 30, 2026, it entered into a binding term sheet with Ascendis Pharma A/S to resolve all pending patent proceedings through a global settlement and royalty-bearing license agreement.